Key Insights on Align Technology Stock

Shares of Health Care sector company Align Technology moved -6.4% today, and are now trading at a price of $254.03. The Large-Cap stock's daily volume was 643,665 compared to its average volume of 677,536. The S&P 500 index returned a -0.0% performance.

Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company is based in Tempe and has 21,670 full time employees. Its market capitalization is $19,123,808,256.

13 analysts are following Align Technology and have set target prices ranging from $250.0 to $400.0 per share. On average, they have given the company a rating of buy. At today's prices, ALGN is trading -24.83% away from its average analyst target price of $337.92 per share.

Over the last year, ALGN shares have gone down by -17.9%, which represents a difference of -41.1% when compared to the S&P 500. The stock's 52 week high is $413.2 per share and its 52 week low is $176.34. With average free cash flows of $515.42 Million that have been growing at an average rate of 5.5% over the last 5 years, Align Technology declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 785,776 177,716 608,060 119.65
2022 568,732 291,900 276,832 -64.12
2021 1,172,544 401,098 771,446 52.08
2020 662,174 154,916 507,258 -15.11
2019 747,270 149,707 597,563 80.33
2018 554,681 223,312 331,369
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.